No Data
Beyond The Numbers: 8 Analysts Discuss Novo Nordisk Stock
Analysts' ratings for Novo Nordisk (NYSE:NVO) over the last quarter vary from bullish to bearish, as provided by 8 analysts.Summarizing their recent assessments, the table below illustrates the evolvi
Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
Cantor Fitzgerald analyst Louise Chen reiterates Novo Nordisk (NYSE:NVO) with a Overweight and maintains $160 price target.
Novo Nordisk Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/01/2024 10.43% Cantor Fitzgerald $160 → $160 Reiterates Overweight → Overweight 06/25/2024 12.5% BMO Ca
Novo Nordisk A/S - Share Repurchase Programme
US drug prices have skyrocketed by 40%! Over 30% of people are 'hopeless sighs' about the high cost of drugs, and Biden is urgently pushing measures to address it.
In the past decade, prescription drug prices in the USA have skyrocketed by nearly 40%, far exceeding inflation rates, resulting in about one-third of Americans being unable to purchase medicine from pharmacies.
Alnylam, Lilly, AstraZeneca Among Best Performing Pharmas, Biotechs in Q2